BridgeMD
New treatment option for Obesity, Abdominal
Official title Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue
ClinicalTrials.gov ID: NCT06627868
What this study is testing
- What it's testing
- A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Willingness to provide informed consent to participate in the BATNAD study
- Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
- Age 30-55 (sedentary lifestyle)
- BMI = 18-25 kg/m2 (normal-weight people)
- BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (people with obesity)
You likely can't join if
- Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg)
- Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)
- Major alterations in the menstrual cycle (e.g., amenorrhea)
- Use of nicotine based products
- Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range)
- Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/)
See the full eligibility criteria
- Willingness to provide informed consent to participate in the BATNAD study
- Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
- Age 30-55 (sedentary lifestyle)
- BMI = 18-25 kg/m2 (normal-weight people)
- BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (people with obesity)
- Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg)
- Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)
- Major alterations in the menstrual cycle (e.g., amenorrhea)
- Use of nicotine based products
- Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range)
- Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/)
- Abnormal oral glucose tolerance test (2h OGTT \> 11.1 mmol/L)
- Hypertension (blood pressure \> 160/100 mmHg)
- Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease)
- Abnormal coagulopathy (e.g., clotting abnormality)
- Malignancies
- Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment)
- Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start
- Vaccination within the 45 days prior to the study start
- Episode of fever or major surgery, burns and traumas within the month prior to the study start
- Chronic infections requiring chronic antibiotic or anti-viral treatment
- Whole blood donation in the last 3 months (\>400 mL of blood) or plans for blood donation during the entire protocol period
- Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study
- Allergy to lidocaine or epinephrine, or other local anaesthetics
- Previous participation to studies where PET or CT method is used
- Use of any medication that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use...
- Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the...
The study team makes the final eligibility decision.
Where it's taking place
- Turku, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Turku, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.